|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
1.170 USD |
-0.85% | +10.38% | -45.07% | |
Published on 06/01/2025 at 10:47
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Allogene Therapeutics, Inc. Announces Asco 2025 Abstract Publication Featuring Oral Presentation of Allo-316 in Kidney Cancer and Alpha3 Tip Poster for Cema-Cel |
May. 22 |
CI |
|
Allogene Therapeutics, Inc., Q1 2025 Earnings Call, May 13, 2025 |
May. 19 |
|
|
Oppenheimer Adjusts Allogene Therapeutics Price Target to $9 From $10, Maintains Outperform Rating |
May. 14 |
MT |
|
Truist Securities Adjusts Allogene Therapeutics Price Target to $10 From $14, Maintains Buy Rating |
May. 14 |
MT |
|
Allogene Therapeutics Inc QTRLY Loss Per Share $0.28 |
May. 13 |
RE |
|
Allogene Therapeutics Reports First Quarter 2025 Financial Results And Business Update |
May. 13 |
RE |
|
Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 13 |
CI |
|
Allogene Therapeutics, Inc. to Present Updated Allo-316 Clinical Results in Kidney Cancer in Oral Presentation and Alpha3 Trial-In-Progress Poster for Cema-Cel At the 2025 American Society of Clinical Oncology Annual Meeting |
Apr. 23 |
CI |
|
Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases |
Apr. 07 |
MT |
|
Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329 |
Apr. 07 |
RE |
|
Allogene Therapeutics, Inc. Receives Three Fast Track Designations from the U.S. Food and Drug Administration |
Apr. 07 |
CI |
|
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) dropped from S&P Biotechnology Select Industry Index |
Mar. 23 |
CI |
|
Allogene Therapeutics Inc Q4 Loss Per Share $0.28 |
Mar. 13 |
RE |
|
Allogene Therapeutics, Inc., Q4 2024 Earnings Call, Mar 13, 2025 |
Mar. 13 |
|
|
Allogene Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Mar. 13 |
CI |
|
Allogene Therapeutics, Inc. Expands Strategic Partnership with Foresight Diagnostics, Inc. to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia |
Feb. 25 |
CI |
|
Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501 |
Feb. 13 |
RE |
|
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 Alpha/Alpha2 Trials of the Allogeneic Car T Cemacabtagene Ansegedleucel/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology |
Feb. 13 |
CI |
|
Allogene Therapeutics, Inc. Announces Executive Changes |
Jan. 29 |
CI |
|
Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate |
Jan. 28 |
MT |
|
Allogene Therapeutics, Inc. Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases |
Jan. 28 |
CI |
|
Allogene Therapeutics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:00 PM |
Jan. 15 |
|
|
Allogene Therapeutics, Inc. Acknowledges the Passing of Founding Board Member David Bonderman |
Dec. 12 |
CI |
|
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology Convergence |
Nov. 18 |
CI |
|
Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel |
Nov. 13 |
CI |
ALLO: Dynamic Chart
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
More about the company
Buy
Average target price
8.200USD
Spread / Average Target
+600.85%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
